Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.02036 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Javier Cortés und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain. Hauptthemen laut MEDLINE: Letrozole, Breast Neoplasms, Pyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
PURPOSE AMEERA-5 investigated amcenestrant (oral selective estrogen receptor [ER] degrader) plus palbociclib versus letrozole plus palbociclib as first-line treatment for ER-positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced/metastatic breast cancer (aBC). MATERIALS AND METHODS In AMEERA-5 (ClinicalTrials.gov identifier: NCT04478266 ), a double-blind, double-dummy, international phase III trial, adult pre-/post-menopausal women and men without previous systemic therapy for ER+/HER2– aBC were randomly assigned 1:1 to amcenestrant 200 mg once daily + standard palbociclib dosage (125 mg once daily, 21 days on/7 days off) or letrozole 2.5 mg once daily + standard palbociclib dosage, stratified by de novo metastatic disease, postmenopausal women, and visceral metastasis. The primary end point was progression-free survival (PFS), compared using a stratified log-rank test with one-sided type I error rate of 2.5%. Secondary end points included overall survival (key secondary), pharmacokinetics, and safety. RESULTS Between October 14, 2020, and December 2, 2021, 1,068 patients were randomly assigned to amcenestrant + palbociclib (N = 534) or letrozole + palbociclib (N = 534). At the interim analysis (median follow-up 8.4 months), the stratified hazard ratio for PFS was 1.209 (95% CI, 0.939 to 1.557; one-sided P value = .9304); therefore, the study was stopped for futility. The 6-month PFS rate was 82.7% (95% CI, 79.0 to 85.8) with amcenestrant + palbociclib versus 86.9% (95% CI, 83.5 to 89.6) with letrozole + palbociclib. In the amcenestrant + palbociclib versus letrozole + palbociclib groups, treatment-emergent adverse events (any grade) occurred in 85.6% versus 85.4% of patients and grade ≥3 events in 46.3% versus 60.8%, respectively. CONCLUSION The AMEERA-5 study was discontinued on the basis of the recommendation of the data monitoring committee at the interim futility analysis. No new safety signals were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.
- Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
- Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.
- Fred Hutchinson Cancer Center, Seattle, WA.
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.
- Institut Gustave Roussy, Villejuif, France.
ORCID-Profile: Javier Cortés, Sara A Hurvitz, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Laure Deyme, Jihane Aouni, Aditya Bardia
Zitieren
APA
Cortés, J., Hurvitz, S. A., O'Shaughnessy, J., Delaloge, S., Iwata, H., Rugo, H. S., Neven, P., Kanagavel, D., Cohen, P., Paux, G., Cartot-Cotton, S., Stefanova-Urena, M., Deyme, L., Aouni, J., Sebastien, B., & Bardia, A. (2024). Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02036
Vancouver
Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, et al. Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02036
BibTeX
@article{Corts2024,
author = {Cortés, Javier and Hurvitz, Sara A and O'Shaughnessy, Joyce and Delaloge, Suzette and Iwata, Hiroji and Rugo, Hope S and Neven, Patrick and Kanagavel, Dheepak and Cohen, Patrick and Paux, Gautier and Cartot-Cotton, Sylvaine and Stefanova-Urena, Maya and Deyme, Laure and Aouni, Jihane and Sebastien, Bernard and Bardia, Aditya},
title = {Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.02036}
}
EUVIMED